Uploaded March 2026 | Updated September 2026, 2 weeks ago
Rare diseases often get overlooked when it comes to drug development — they're usually expensive and challenging to study. New AI tools are changing that.
In this clip, Jack Hidary, CEO of SandboxAQ, and Nadia Harhen, Head of AI Simulation, explain the company's recent end-to-end drug partnership with Bahrain, and how simulation-first approaches are enabling sovereign nations — and even academic labs — to take drug development further than ever before.
For the first time, researchers may not have to stop at early discovery and hand off control.
AI isn’t just accelerating timelines. It’s changing who gets to carry a therapy forward.
Watch the full interview here: youtu.be/T35wzsZVsM0
#sandboxaq #lqms #aqbiosim
Rare diseases often get overlooked when it comes to drug development — they're usually expensive and challenging to study. New AI tools are changing that.
In this clip, Jack Hidary, CEO of SandboxAQ, and Nadia Harhen, Head of AI Simulation, explain the company's recent end-to-end drug partnership with Bahrain, and how simulation-first approaches are enabling sovereign nations — and even academic labs — to take drug development further than ever before.
For the first time, researchers may not have to stop at early discovery and hand off control.
AI isn’t just accelerating timelines. It’s changing who gets to carry a therapy forward.
Watch the full interview here: youtu.be/T35wzsZVsM0
#sandboxaq #lqms #aqbiosim
